The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Leach, M O, Brindle, K M, Evelhoch, J L, Griffiths, J R, Horsman, M R, Jackson, A, Jayson, G C, Judson, I R, Knopp, M V, Maxwell, R J, McIntyre, D, Padhani, A R, Price, P, Rathbone, R, Rustin, G J, Tofts, P S, Tozer, G M, Vennart, W, Waterton, J C, Williams, S R, Workman, P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Workshop Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362033/
https://www.ncbi.nlm.nih.gov/pubmed/15870830
http://dx.doi.org/10.1038/sj.bjc.6602550
Descripción
Sumario:Vascular and angiogenic processes provide an important target for novel cancer therapeutics. Dynamic contrast-enhanced magnetic resonance imaging is being used increasingly to noninvasively monitor the action of these therapeutics in early-stage clinical trials. This publication reports the outcome of a workshop that considered the methodology and design of magnetic resonance studies, recommending how this new tool might best be used.

Ejemplares similares